Study Stopped
Poor accrual
Genetic Study of Brain Tumors in Young Children
INI1 Mutation Analysis and Expression Profiling of Embryonal CNS Tumors
2 other identifiers
observational
38
1 country
4
Brief Summary
RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Genetic study to understand how genes may be involved in the development of brain tumors in young children.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2001
Typical duration for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 2, 2001
CompletedStudy Start
First participant enrolled
March 1, 2001
CompletedFirst Posted
Study publicly available on registry
January 27, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2004
CompletedJuly 20, 2011
July 1, 2011
3.4 years
February 2, 2001
July 19, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Deletions and mutations of the INI1 gene in infants with AT/RT, medulloblastoma, PNET, or choroid plexus carcinoma
Eligibility Criteria
Tissue samples from infants (\< 3 years old) with histologically confirmed primary intracranial CNS medulloblastoma/PNET, atypical teratoid/rhabdoid tumor, or choroid plexus carcinoma and with no prior chemotherapy, radiotherapy, or treatment from any other investigational agent will be used for this research study. Patients who meet the eligibility criteria, are treated at a PBTC institution that has IRB approval of this study, and consent to the usage of stored tumor specimens for the study objectives constitute the study population.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
- Pediatric Brain Tumor Consortiumlead
- National Cancer Institute (NCI)collaborator
Study Sites (4)
Children's National Medical Center
Washington D.C., District of Columbia, 20010-2970, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104-4318, United States
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Texas Children's Cancer Center
Houston, Texas, 77030-2399, United States
Related Publications (1)
Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002 Jan 24;415(6870):436-42. doi: 10.1038/415436a.
PMID: 11807556RESULT
Biospecimen
Tumor samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Jaclyn A. Biegel, PhD
Children's Hospital of Philadelphia
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- NETWORK
Study Record Dates
First Submitted
February 2, 2001
First Posted
January 27, 2003
Study Start
March 1, 2001
Primary Completion
August 1, 2004
Study Completion
August 1, 2004
Last Updated
July 20, 2011
Record last verified: 2011-07